SCHEDULE 13G/A: Lynx1 Capital Management Discloses 10.9% Stake in TScan Therapeutics
Beneficial Ownership Disclosure
Lynx1 Capital Management LP and Weston Nichols have disclosed a beneficial ownership of 10.9% in TScan Therapeutics, Inc., totaling 5,357,347 shares of Voting Common Stock as of December 31, 2024.
Summary
- Lynx1 Capital Management LP and Weston Nichols (collectively, the "Reporting Persons") have filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in TScan Therapeutics, Inc.
- As of December 31, 2024, the Reporting Persons collectively beneficially own 5,357,347 shares of TScan Therapeutics, Inc.'s Voting Common Stock.
- This ownership represents 10.9% of the outstanding Voting Common Stock of TScan Therapeutics, Inc.
- The percentage is calculated based on 49,094,006 shares of Voting Common Stock outstanding as of November 7, 2024, as reported in the Company's Form 10-Q for the quarter ended September 30, 2024.
- Both Lynx1 Capital Management LP and Weston Nichols share voting and dispositive power over all 5,357,347 shares.
- The filing certifies that the securities were not acquired or held for the purpose of changing or influencing control of the issuer, nor in connection with any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.
Sentiment
Score: 6
Explanation: The document is a factual disclosure of beneficial ownership. The acquisition of a significant stake (10.9%) by an institutional investor can be viewed as a positive signal of confidence in the company, although the filing itself is neutral in tone and purpose (passive investment).
Future Outlook
NA
Industry Context
This Schedule 13G filing indicates a significant passive investment by Lynx1 Capital Management LP and Weston Nichols in TScan Therapeutics, Inc. Such filings are common in the investment landscape, reflecting institutional interest in publicly traded companies. Without further context on TScan Therapeutics' specific industry (e.g., biotechnology, pharmaceuticals), it's difficult to draw broader industry trends, but large institutional stakes often signal confidence in a company's long-term prospects within its sector.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional stake by Lynx1 Capital Management and Weston Nichols may be viewed positively by existing shareholders, potentially signaling confidence in TScan Therapeutics' value and future prospects. It could also influence trading activity and share price.
Key Dates
| Date | Description |
|---|---|
| 2024-09-30 | End of quarterly period for which TScan Therapeutics, Inc. filed its Form 10-Q. |
| 2024-11-07 | Date as of which 49,094,006 shares of Voting Common Stock were reported outstanding in TScan Therapeutics, Inc.'s Form 10-Q. |
| 2024-11-12 | Date TScan Therapeutics, Inc. filed its Quarterly Report on Form 10-Q for the period ended September 30, 2024. |
| 2024-12-31 | Date of event which requires filing of this Schedule 13G statement. |
| 2025-02-14 | Date the Schedule 13G statement was signed by Lynx1 Capital Management LP and Weston Nichols. |
Keywords
TScan Therapeutics, Lynx1 Capital Management, Weston Nichols, Schedule 13G, Beneficial Ownership, Institutional Investor, SEC Filing, Voting Common Stock, Shareholding
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.